专家组共识意见:抗炎药物在2型糖尿病管理中的作用
本文为印度专家组关于抗炎药物在2型糖尿病管理中作用的共识意见。文章回顾了炎症作为2型糖尿病发病因素及微血管并发症、动脉粥样硬化驱动因素的证据,指出现有降糖方案在成本、依从性和安全性方面的局限。文中汇总了卡那奴单抗、阿那白滞素、依那西普等选择性抗炎药对血糖参数影响有限,而羟氯喹被显示可降低HbA1c 0.87%;一项纳入4905例类风湿关节炎患者、随访21.5年的前瞻性观察性研究显示,使用羟氯喹超过4年者糖尿病风险较未使用者低77%(RR 0.23;95%CI 0.11-0.50)。2014年羟氯喹400 mg获DCGI批准作为饮食和运动的辅助,用于改善二甲双胍联合磺脲类治疗的2型糖尿病患者的血糖控制。
要点
- 羟氯喹400 mg获DCGI批准作为饮食和运动的辅助,用于改善二甲双胍联合磺脲类治疗的2型糖尿病患者的血糖控制。
- 一项纳入4905例无糖尿病的类风湿关节炎成人、随访21.5年的前瞻性观察性研究显示,使用羟氯喹超过4年者糖尿病风险较未使用者低77%(RR 0.23;95%CI 0.11-0.50)。
- 羟氯喹作为广谱抗炎药被显示可降低HbA1c 0.87%。
- 卡那奴单抗对HbA1c无一致的长期获益;阿那白滞素和依那西普对血糖参数和胰岛素敏感性的影响有限。
- 在亚洲多国研究中,约50%的印度受访者糖尿病控制不佳;胰岛素因高成本和依从性差使用受限,GLP1激动剂、胰岛素类似物和SGLT2抑制剂因仍处专利期而价格高昂。
适用人群与场景
- 接受二甲双胍联合磺脲类治疗但血糖控制不佳的2型糖尿病患者(羟氯喹获批适应人群)。
- 类风湿关节炎和系统性红斑狼疮患者(羟氯喹广泛用于治疗这些疾病)。
- 无糖尿病的类风湿关节炎成人(前瞻性观察性研究人群,共4905例,随访21.5年)。
处置流程与药物剂量
- 羟氯喹400 mg获DCGI批准作为饮食和运动的辅助,用于改善二甲双胍联合磺脲类治疗的2型糖尿病患者的血糖控制。
- 对两种口服药联合治疗控制不佳的患者,治疗选择为加用第三种口服药或胰岛素;胰岛素因高成本和依从性差使用受限。
- 噻唑烷二酮类药物与液体潴留和体重增加相关,可能引起或加重水肿和充血性心力衰竭。
红旗征与不能漏的情况
- 噻唑烷二酮类药物与液体潴留和体重增加相关,可能引起或加重水肿和充血性心力衰竭。
研究设计与关键结果
- 本文为专家组共识意见,回顾了慢性低脂性炎症作为2型糖尿病发病因素的证据,以及抗炎治疗在2型糖尿病和心血管疾病中的研究兴趣。
- CANTOS研究中,卡那奴单抗(选择性高亲和力全人源单克隆抗体,抑制IL-1β)对HbA1c无一致的长期获益。
- 阿那白滞素(IL-1受体拮抗剂)和依那西普(TNF抑制剂)对血糖参数和胰岛素敏感性的影响有限。
- 羟氯喹作为广谱抗炎药被显示可降低HbA1c 0.87%。
- 一项纳入4905例无糖尿病的类风湿关节炎成人、随访21.5年的前瞻性观察性研究显示,使用羟氯喹超过4年者糖尿病风险较未使用者低77%(RR 0.23;95%CI 0.11-0.50)。
- 在亚洲多国研究中,约50%的印度受访者糖尿病控制不佳。
证据类型、等级与局限
- 证据类型:专家组共识意见(Expert Group Consensus Opinion)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 专家组基于炎症在2型糖尿病发病中的作用,讨论了抗炎药物作为2型糖尿病辅助治疗的潜在价值。
- 羟氯喹400 mg已获DCGI批准作为饮食和运动的辅助,用于改善二甲双胍联合磺脲类治疗的2型糖尿病患者的血糖控制。
- 原文指出需要一种安全且廉价的治疗选择用于控制不佳的2型糖尿病管理。
指南或共识出处
- Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D),发表于J Assoc Physicians India。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Diabetes is a major public health emergency of the 21st century. Results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study have found prevalence of diabetes and prediabetes in India to be as high as 7.3% and 10.3%, respectively with nation-wide projection of 77.2 million people with prediabetes and 69.2 million with diabetes. It is well established that insulin resistance (IR) and islet β-cell failure are the two major features of T2D Multiple mechanisms including glucotoxicity, lipotoxicity, oxidative stress, endoplasmic reticulum stress, formation of amyloid deposits in the islets, etc. have been hypothesized to participate in the pathology of the disease. In the concluding decade of the last century, numerous studies - prospective and cross-sectional, have confirmed the role of chronic low-grade inflammation as a pathogenetic factor of T2D. It has been shown that increased levels of various inflammatory markers and mediators including fundamental markers like white blood cell count, C-reactive protein (CRP) to the more specific circulating cytokines like, interleukin-6 (IL-6), IL-1β, plasminogen activator inhibitor-1 (PAI-1), etc. correlate with incident T2D. Based on the robust evidence implying the role of inflammation in T2D pathogenesis, several studies have proven that the proinflammatory cytokines play a central role in the development of microvascular diabetic complications such as nephropathy, retinopathy, and neuropathy. Inflammation in T2D causes accelerated atherosclerosis which predisposes to CVD, the leading cause of mortality in these patients. Recently there is a considerable increase in the interest among the researchers about anti-inflammatory therapies in the setting of chronic disorders such as T2D and CV diseases. In a multi-country study conducted in Asia, approximately 50% of Indian respondents had poor diabetes control. Most patients initially respond to sulfonylurea and/or metformin, and later these agents lose their effectiveness with time. Therapeutic option in patients uncontrolled on two-drug combination therapy is either to add third oral drug or insulin. However, use of insulin is limited due to its high cost and poor compliance. Majority of new treatment options like GLP1 agonists, insulin analogs and SGLT2 inhibitors are costly considering they are still under patent. The thiazolidinedione class of drugs is associated with adverse effects like fluid retention and weight gain that may result in or exacerbate edema and congestive heart failure. Thus there is a need for a safe and inexpensive treatment option for the management of uncontrolled T2D. Considering the role of inflammation in T2D pathogenesis, the drug should not only have antihyperglycemic effects but also reduce inflammatory burden thus reducing the progression and complications of T2D. The current interest is apparently directed towards drugs targeting inflammation acting at different stages of the inflammatory cascade. In the recently published CANTOS study, canakinumab, a selective, high-affinity, fully human monoclonal antibody which inhibits IL-1β, has no consistent long-term benefits on HbA1c. Other selective inhibitors like anakinra (IL-1 receptor antagonist) and etanercept (TNF inhibitor) too have yielded modest effects on glycemic parameters and insulin sensitivity. However, hydroxychloroquine (HCQ), a broad anti-inflammatory agent has been shown to reduce HbA1c by 0.87%. Hydroxychloroquine (HCQ) is considered as one of the safest disease modifying anti-rheumatic drug, used widely for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The effect of HCQ in preventing development of diabetes in patients with chronic inflammatory diseases was highlighted in a prospective observational study of 4905 adults with rheumatoid arthritis and no diabetes with 21.5 years of follow-up. Patients who took HCQ for more than 4 years had a significant 77% lower risk of diabetes compared with non users of HCQ (RR, 0.23; 95% CI, 0.11-0.50). Taking cue from this study highlighting the anti-diabetic effect of HCQ, pioneering research studies evaluating these effects of HCQ were conducted in India. In 2014, hydroxychloroquine 400 mg got DCGI approval as an adjunct to diet and exercise to improve glycemic control of patients on metformin, sulfonylurea combination in Type 2 diabetes.
参考来源
- Das AK, Kalra S, Tiwaskar M, et al. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D). J Assoc Physicians India. 2019. PMID: 31801334
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。